A multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of Siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with Multicentric Castleman's disease

被引：0

作者：

Hess, G. ^{[1
]}

Kirsch, A. ^{[2
]}

Wong, R. S. ^{[3
]}

Casper, C. ^{[4
]}

Munshi, N. ^{[5
]}

Fossa, A. ^{[6
]}

Cavet, J. ^{[7
]}

Bandekar, R. ^{[8
]}

Rothman, M. ^{[9
]}

Puchalski, T. A.

Chaturvedi, S.

van de Velde, H. ^{[10
]}

Vermeulen, J. ^{[11
]}

van Rhee, F. ^{[12
]}

机构：

[1] Johannes Gutenberg Univ Mainz, Med Klin & Poliklin 3, D-55122 Mainz, Germany

[2] Med Versorgungszentrum Onkol Schwerpunkt Oskar He, Berlin, Germany

[3] Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China

[4] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[5] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Norwegian Radium Hosp, Oslo, Norway

[7] Christie NHS Fdn Trust, Manchester, Lancs, England

[8] Janssen Res & Dev, Spring House, PA USA

[9] Janssen Res & Dev, Washington, DC USA

[10] Janssen Res & Dev, Beerse, Belgium

[11] Janssen Res & Dev, Leiden, Netherlands

[12] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P251

引用

页码：77 / 77

页数：1

共 50 条

[1] A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy and Safety Of Siltuximab, An Anti-Interleukin-6 Monoclonal Antibody, In Patients With Multicentric Castleman's Disease
Wong, Raymond S.
Casper, Corey
Munshi, Nikhil
Ke, Xiaoyan
Fossa, Alexander
Simpson, David
Capra, Marcelo
Liu, Ting
Hsieh, Ruey Kuen
Goh, Yeow Tee
Zhu, Jun
Cho, Seok-Goo
Ren, Hanyun
Cavet, James
Bandekar, Rajesh
Rothman, Margaret
Puchalski, Thomas A.
Chaturvedi, Shalini
de Velde, Helgi van
Vermeulen, Jessica
van Rhee, Frits
BLOOD, 2013, 122 (21)
[2] Recruitment in a randomized, double-blind, placebo-controlled study to assess siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in patients with multicentric Castleman's disease.
Van Rhee, Frits
Capra, Marcelo
Wong, Raymond
Vermeulen, Jessica
Safer, Karim
Todorovic, Marija
Rhoten, Patricia
Van de Velde, Helgi
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[3] Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
van Rhee, Frits
Wong, Raymond S.
Munshi, Nikhil
Rossi, Jean-Francois
Ke, Xiao-Yan
Fossa, Alexander
Simpson, David
Capra, Marcelo
Liu, Ting
Hsieh, Ruey Kuen
Goh, Yeow Tee
Zhu, Jun
Cho, Seok-Goo
Ren, Hanyun
Cavet, James
Bandekar, Rajesh
Rothman, Margaret
Puchalski, Thomas A.
Reddy, Manjula
van de Velde, Helgi
Vermeulen, Jessica
Casper, Corey
LANCET ONCOLOGY, 2014, 15 (09): : 966 - 974
[4] Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease
Casper, Corey
Chaturvedi, Shalini
Munshi, Nikhil
Wong, Raymond
Qi, Ming
Schaffer, Michael
Bandekar, Rajesh
Hall, Brett
van de Velde, Helgi
Vermeulen, Jessica
Reddy, Manjula
van Rhee, Frits
CLINICAL CANCER RESEARCH, 2015, 21 (19) : 4294 - 4304
[5] Siltuximab, a Novel Anti-Interleukin-6 Monoclonal Antibody, for Castleman's Disease
van Rhee, Frits
Fayad, Luis
Voorhees, Peter
Furman, Richard
Lonial, Sagar
Borghaei, Hossein
Sokol, Lubomir
Crawford, Julie
Cornfeld, Mark
Qi, Ming
Qin, Xiang
Herring, Jennifer
Casper, Corey
Kurzrock, Razelle
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (23) : 3701 - 3708
[6] INFLAMMATORY AND ANEMIA-RELATED MARKERS IN A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF SILTUXIMAB (ANTI-IL-6 MONOCLONAL ANTIBODY) IN MULTICENTRIC CASTLEMAN'S DISEASE PATIENTS
Casper, C.
Chaturvedi, S.
Munshi, N.
Wong, R.
Qi, M.
Schaffer, M.
Bandekar, R.
Huang, Y.
Hall, B.
Vermeulen, J.
Reddy, M.
Van Rhee, F.
HAEMATOLOGICA, 2014, 99 : 465 - 465
[7] A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease
van Rhee, Frits
Casper, Corey
Voorhees, Peter M.
Fayad, Luis E.
de Velde, Helgi van
Vermeulen, Jessica
Qin, Xiang
Qi, Ming
Tromp, Brenda
Kurzrock, Razelle
ONCOTARGET, 2015, 6 (30) : 30408 - 30419
[8] A randomized, double-blind, placebo-controlled study to assess the effectivity and safety of IL-6 inhibition by Siltuximab (CNTO-328) in patients with multicentric Castleman's disease
Fingerle-Rowson, G.
Vermeulen, J.
Qi, M.
Safer, K.
Godwin, A.
Prince, H. M.
Rossi, J. F.
Cornfeld, M.
van Rhee, F.
ONKOLOGIE, 2010, 33 : 253 - 254
[9] An Open-Label, Phase 2, Multicenter Study Of The Safety Of Long-Term Treatment With Siltuximab (an Anti-Interleukin-6 Monoclonal Antibody) In Patients With Multicentric Castleman's Disease
Van Rhee, Frits
Casper, Corey
Voorhees, Peter M.
Fayad, Luis E.
van de Velde, Helgi
Vermeulen, Jessica
Qin, Xiang
Qi, Ming
Tromp, Brenda
Kurzrock, Razelle
BLOOD, 2013, 122 (21)
[10] Deriving health utility values from a randomized, double-blind, placebo-controlled trial of siltuximab in subjects with multicentric Castleman's disease
Vernon, Margaret
Robinson, Don, Jr.
Trundell, Dylan
Ishak, Jack
Jen, Min-Hua
Brazier, John
CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (07) : 1193 - 1200

← 1 2 3 4 5 →